The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
November 11, 2021
Liquid biopsy is a powerful tool for matching cancer patients with targeted therapies and for cancer recurrence monitoring.
November 4, 2021
The use of genomic profiling and testing in cancer is helping clinicians and patients better understand the key drivers of a patient’s tumour and inform more precise treatment decisions.
November 1, 2021
FOUNTAIN VALLEY, Calif.
October 14, 2021
The FDA is now approving biomarker-informed therapies on a routine basis, yet there is significant disparity in patient access to molecular profiling that would match cancer patients to these targeted treatments.
September 14, 2021
OncoHelix and Canexia Health, are partnering to help Canadian cancer patients gain access to precision genomic testing via their oncologist. Using a circulating tumour DNA (ctDNA) or “liquid biopsy” blood sample, the partnership allows for Canexia Health’s Follow It® ctDNA 38-gene panel to be accessed through OncoHelix for testing services.
September 3, 2021
Canexia Health CEO, Michael Ball, joined Bio Asia Pacific 2021 to discuss global expansion of the company’s liquid biopsy initiative, Project ACTT (Access to Cancer Testing & Treatment).
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.
